UA-30 mitigates systemic aging and motor decline by inhibiting RalA signaling in naturally aged mice.

UA-30 delays systemic aging and improves muscle function in naturally aged mice by inhibiting RalA signaling, reducing fibrosis, and extending lifespan.

• Why it matters: Aging involves progressive decline and systemic dysfunction, with limited therapeutic options for age-related diseases like sarcopenia that feature muscle fibrosis and degeneration.
• What they did: Researchers identified UA-30 as a safe, pharmacokinetically favorable compound that, after 10 weeks of treatment in 18.5-month-old mice, reduced fibrosis and muscle atrophy, and targeted RalA through proteomic and functional analyses.
• The result: Inhibition of RalA activity by UA-30 suppressed pro-fibrotic signaling, improved mitochondrial functions, and extended lifespan, suggesting UA-30 and RalA as promising targets for combating age-related muscle decline.